| Year |
Citation |
Score |
| 2020 |
Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ. Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32353194 DOI: 10.1002/Mds.28046 |
0.349 |
|
| 2019 |
Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Sarna J, Monchi O, Duval C. Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. Frontiers in Neurology. 10: 256. PMID 30967832 DOI: 10.3389/Fneur.2019.00256 |
0.311 |
|
| 2019 |
Lebel K, Goubault E, Bogard S, Duval C, Blanchet PJ. Parkinson's disease patients experiencing peak-dose dyskinesia redistribute involuntary movements throughout their body to improve motor control. Parkinsonism & Related Disorders. PMID 30935827 DOI: 10.1016/J.Parkreldis.2019.03.016 |
0.345 |
|
| 2019 |
Hernandez G, Mahmoudi S, Cyr M, Diaz J, Blanchet PJ, Lévesque D. Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30675935 DOI: 10.1002/Mds.27630 |
0.716 |
|
| 2018 |
Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Langlois M, Duval C. Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia: Parkinson's Symptoms Coexist with Dyskinesia. Journal of Parkinson's Disease. PMID 29843253 DOI: 10.3233/Jpd-181312 |
0.31 |
|
| 2017 |
Lévesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, Blanchet PJ, Lévesque D. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. Neuroscience. PMID 28790021 DOI: 10.1016/J.Neuroscience.2017.07.068 |
0.734 |
|
| 2015 |
Mongeon D, Blanchet P, Bergeron S, Messier J. Impact of Parkinson's disease on proprioceptively based on-line movement control. Experimental Brain Research. PMID 26055990 DOI: 10.1007/S00221-015-4343-4 |
0.716 |
|
| 2014 |
Mahmoudi S, Lévesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1125-33. PMID 24838395 DOI: 10.1002/Mds.25909 |
0.72 |
|
| 2013 |
Mahmoudi S, Blanchet PJ, Lévesque D. Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia. The European Journal of Neuroscience. 38: 2192-8. PMID 23551242 DOI: 10.1111/Ejn.12198 |
0.726 |
|
| 2013 |
Mongeon D, Blanchet P, Messier J. Impact of Parkinson's disease and dopaminergic medication on adaptation to explicit and implicit visuomotor perturbations. Brain and Cognition. 81: 271-82. PMID 23313834 DOI: 10.1016/J.Bandc.2012.12.001 |
0.704 |
|
| 2010 |
Tremblay PL, Bedard MA, Langlois D, Blanchet PJ, Lemay M, Parent M. Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease. Experimental Brain Research. 205: 375-85. PMID 20680249 DOI: 10.1007/S00221-010-2372-6 |
0.376 |
|
| 2009 |
Philibert M, Richer F, Blanchet PJ, Chouinard S, Dubarry AS, Fimbel E. Movement irregularities in atypical parkinsonian syndromes. Parkinsonism & Related Disorders. 15: 542-5. PMID 19103504 DOI: 10.1016/J.Parkreldis.2008.11.004 |
0.353 |
|
| 2009 |
Tremblay PL, Bedard MA, Levesque M, Chebli M, Parent M, Courtemanche R, Blanchet PJ. Motor sequence learning in primate: role of the D2 receptor in movement chunking during consolidation. Behavioural Brain Research. 198: 231-9. PMID 19041898 DOI: 10.1016/J.Bbr.2008.11.002 |
0.332 |
|
| 2009 |
Mongeon D, Blanchet P, Messier J. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing. Neuroscience. 158: 426-40. PMID 18996173 DOI: 10.1016/J.Neuroscience.2008.10.013 |
0.719 |
|
| 2004 |
Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, Bédard MA. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28: 31-9. PMID 14687854 DOI: 10.1016/S0278-5846(03)00172-6 |
0.38 |
|
| 2003 |
Lemay S, Blanchet P, Chouinard S, Masson H, Soland V, Bédard MA. Poor tolerability of a transdermal nicotine treatment in Parkinson's disease. Clinical Neuropharmacology. 26: 227-9. PMID 14520160 DOI: 10.1097/00002826-200309000-00004 |
0.394 |
|
| 2003 |
Blanchet PJ. Antipsychotic drug-induced movement disorders. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 30: S101-7. PMID 12691483 |
0.329 |
|
| 1999 |
Blanchet PJ. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. S21-6. PMID 10451756 DOI: 10.1017/S0317167100000056 |
0.32 |
|
| 1998 |
Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14: 75-82. PMID 9871445 DOI: 10.1007/BF01345246 |
0.355 |
|
| 1998 |
Morissette M, Goulet M, Grondin R, Blanchet P, Bédard PJ, Di Paolo T, Lévesque D. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. The European Journal of Neuroscience. 10: 2565-73. PMID 9767387 DOI: 10.1046/J.1460-9568.1998.00264.X |
0.311 |
|
| 1998 |
Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology. 51: S30-5. PMID 9711978 DOI: 10.1212/Wnl.51.2_Suppl_2.S30 |
0.337 |
|
| 1996 |
Blanchet PJ, Grondin R, Bédard PJ, Shiosaki K, Britton DR. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. European Journal of Pharmacology. 309: 13-20. PMID 8864687 DOI: 10.1016/0014-2999(96)00309-3 |
0.336 |
|
| 1996 |
Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Research. 719: 129-37. PMID 8782872 DOI: 10.1016/0006-8993(96)00157-6 |
0.311 |
|
| 1996 |
Blanchet PJ, Grondin R, Bédard PJ. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 91-4. PMID 8771074 DOI: 10.1002/mds.870110117 |
0.35 |
|
| 1996 |
Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 257-60. PMID 8723141 DOI: 10.1002/mds.870110307 |
0.362 |
|
| 1996 |
Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen JS, Iadarola MJ, St-Jean M, Wigle N, Blanchet P, Grondin R, Robertson GS. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. The European Journal of Neuroscience. 8: 365-81. PMID 8714707 DOI: 10.1111/J.1460-9568.1996.Tb01220.X |
0.405 |
|
| 1996 |
Blanchet PJ, Gomez-Mancilla B, Di Paolo T, Bédard PJ. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Fundamental & Clinical Pharmacology. 9: 434-42. PMID 8617407 DOI: 10.1111/J.1472-8206.1995.Tb00518.X |
0.484 |
|
| 1995 |
Kebabian JW, Blanchet PJ, Bedard P. The D-1 dopamine receptor: past, present and future an idiosyncratic review. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 19: 757-78. PMID 8539418 DOI: 10.1016/0278-5846(95)00129-J |
0.335 |
|
| 1995 |
Bédard PJ, Gomez-Mancilla B, Blanchet P, Grondin R, DiPaolo T. Dopamine-Receptor Families and the Treatment of Parkinsonʼs Disease Clinical Neuropharmacology. 18. DOI: 10.1097/00002826-199501001-00019 |
0.336 |
|
| Show low-probability matches. |